- Home
- FBYD vs LRMR Comparison
FBYD vs LRMR Comparison
Compare FBYD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- LRMR
- Stock Information
- Founded
- FBYD 2021
- LRMR N/A
- Country
- FBYD United States
- LRMR United States
- Employees
- FBYD N/A
- LRMR N/A
- Industry
- FBYD
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- LRMR Health Care
- Exchange
- FBYD Nasdaq
- LRMR Nasdaq
- Market Cap
- FBYD 224.6M
- LRMR 204.9M
- IPO Year
- FBYD N/A
- LRMR N/A
- Fundamental
- Price
- FBYD $7.62
- LRMR $3.88
- Analyst Decision
- FBYD
- LRMR Strong Buy
- Analyst Count
- FBYD 0
- LRMR 7
- Target Price
- FBYD N/A
- LRMR $17.86
- AVG Volume (30 Days)
- FBYD 9.7K
- LRMR 892.3K
- Earning Date
- FBYD 08-12-2025
- LRMR 08-06-2025
- Dividend Yield
- FBYD N/A
- LRMR N/A
- EPS Growth
- FBYD N/A
- LRMR N/A
- EPS
- FBYD N/A
- LRMR N/A
- Revenue
- FBYD $6,937,000.00
- LRMR N/A
- Revenue This Year
- FBYD N/A
- LRMR N/A
- Revenue Next Year
- FBYD N/A
- LRMR N/A
- P/E Ratio
- FBYD $491.11
- LRMR N/A
- Revenue Growth
- FBYD N/A
- LRMR N/A
- 52 Week Low
- FBYD $3.62
- LRMR $1.61
- 52 Week High
- FBYD $13.25
- LRMR $9.88
- Technical
- Relative Strength Index (RSI)
- FBYD 63.89
- LRMR 69.65
- Support Level
- FBYD $7.08
- LRMR $3.11
- Resistance Level
- FBYD $8.16
- LRMR $4.01
- Average True Range (ATR)
- FBYD 0.60
- LRMR 0.27
- MACD
- FBYD 0.16
- LRMR 0.03
- Stochastic Oscillator
- FBYD 72.01
- LRMR 85.64
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.